Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.15
ZTS's Cash to Debt is ranked lower than
90% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.66 vs. ZTS: 0.15 )
Ranked among companies with meaningful Cash to Debt only.
ZTS' s 10-Year Cash to Debt Range
Min: 0.1  Med: 0.19 Max: N/A
Current: 0.15
Equity to Asset 0.20
ZTS's Equity to Asset is ranked lower than
93% of the 562 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. ZTS: 0.20 )
Ranked among companies with meaningful Equity to Asset only.
ZTS' s 10-Year Equity to Asset Range
Min: 0.12  Med: 0.20 Max: 0.69
Current: 0.2
0.12
0.69
Interest Coverage 8.07
ZTS's Interest Coverage is ranked lower than
81% of the 374 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2065.49 vs. ZTS: 8.07 )
Ranked among companies with meaningful Interest Coverage only.
ZTS' s 10-Year Interest Coverage Range
Min: 2.3  Med: 7.55 Max: 13.28
Current: 8.07
2.3
13.28
F-Score: 6
Z-Score: 4.61
M-Score: -2.67
WACC vs ROIC
7.77%
16.00%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 19.73
ZTS's Operating margin (%) is ranked higher than
81% of the 658 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.76 vs. ZTS: 19.73 )
Ranked among companies with meaningful Operating margin (%) only.
ZTS' s 10-Year Operating margin (%) Range
Min: -4.53  Med: 13.66 Max: 19.73
Current: 19.73
-4.53
19.73
Net-margin (%) 12.38
ZTS's Net-margin (%) is ranked higher than
73% of the 659 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.90 vs. ZTS: 12.38 )
Ranked among companies with meaningful Net-margin (%) only.
ZTS' s 10-Year Net-margin (%) Range
Min: -3.62  Med: 7.93 Max: 12.18
Current: 12.38
-3.62
12.18
ROE (%) 47.14
ZTS's ROE (%) is ranked higher than
95% of the 685 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.19 vs. ZTS: 47.14 )
Ranked among companies with meaningful ROE (%) only.
ZTS' s 10-Year ROE (%) Range
Min: 11.26  Med: 16.74 Max: 51.8
Current: 47.14
11.26
51.8
ROA (%) 9.13
ZTS's ROA (%) is ranked higher than
73% of the 705 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. ZTS: 9.13 )
Ranked among companies with meaningful ROA (%) only.
ZTS' s 10-Year ROA (%) Range
Min: 7.28  Med: 8.22 Max: 8.86
Current: 9.13
7.28
8.86
ROC (Joel Greenblatt) (%) 32.23
ZTS's ROC (Joel Greenblatt) (%) is ranked higher than
74% of the 703 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.97 vs. ZTS: 32.23 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ZTS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 25.88  Med: 31.26 Max: 34.3
Current: 32.23
25.88
34.3
Revenue Growth (3Y)(%) 4.00
ZTS's Revenue Growth (3Y)(%) is ranked lower than
58% of the 541 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. ZTS: 4.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ZTS' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: 4.00 Max: 8.4
Current: 4
0
8.4
EBITDA Growth (3Y)(%) 21.40
ZTS's EBITDA Growth (3Y)(%) is ranked higher than
77% of the 483 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.80 vs. ZTS: 21.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ZTS' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0  Med: 21.40 Max: 36.2
Current: 21.4
0
36.2
EPS Growth (3Y)(%) 33.30
ZTS's EPS Growth (3Y)(%) is ranked higher than
84% of the 451 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. ZTS: 33.30 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ZTS' s 10-Year EPS Growth (3Y)(%) Range
Min: 0  Med: 33.30 Max: 66.2
Current: 33.3
0
66.2
» ZTS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

ZTS Guru Trades in Q3 2014

Bill Ackman 5,536,862 sh (New)
John Keeley 79,504 sh (+6.71%)
Robert Olstein 178,000 sh (unchged)
Pioneer Investments 2,203,980 sh (unchged)
Vanguard Health Care Fund 10,798,417 sh (unchged)
Joel Greenblatt Sold Out
First Eagle Investment 2,174,162 sh (-0.13%)
Ruane Cunniff 173,322 sh (-0.14%)
RS Investment Management 2,491,074 sh (-2.27%)
George Soros 4,031,735 sh (-8.09%)
Mario Gabelli 217,980 sh (-10.29%)
» More
Q4 2014

ZTS Guru Trades in Q4 2014

Steven Cohen 1,718,300 sh (New)
Jim Simons 650,500 sh (New)
Bill Ackman 41,569,646 sh (+650.78%)
Mario Gabelli 626,893 sh (+187.59%)
George Soros 4,106,735 sh (+1.86%)
Ruane Cunniff 173,423 sh (+0.06%)
Bill Ackman 41,823,145 sh (unchged)
Pioneer Investments 2,202,773 sh (-0.05%)
Vanguard Health Care Fund 9,178,657 sh (-15.00%)
Robert Olstein 141,000 sh (-20.79%)
John Keeley 62,164 sh (-21.81%)
First Eagle Investment 820,467 sh (-62.26%)
RS Investment Management 212,262 sh (-91.48%)
» More
Q1 2015

ZTS Guru Trades in Q1 2015

Paul Tudor Jones 8,800 sh (New)
Louis Moore Bacon 55,000 sh (New)
Caxton Associates 100,000 sh (New)
Jim Simons 1,822,794 sh (+180.21%)
Pioneer Investments 2,879,512 sh (+30.72%)
Bill Ackman 41,823,145 sh (+0.61%)
George Soros 4,106,735 sh (unchged)
First Eagle Investment 820,467 sh (unchged)
Robert Olstein 141,000 sh (unchged)
Bill Ackman 41,823,145 sh (unchged)
RS Investment Management Sold Out
John Keeley 61,856 sh (-0.50%)
Mario Gabelli 614,785 sh (-1.93%)
Ruane Cunniff 139,936 sh (-19.31%)
Vanguard Health Care Fund 6,175,407 sh (-32.72%)
Steven Cohen 142,400 sh (-91.71%)
» More
2015

ZTS Guru Trades in 2015

Bill Ackman 41,823,145 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with ZTS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 41.35
ZTS's P/E(ttm) is ranked lower than
58% of the 472 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 34.90 vs. ZTS: 41.35 )
Ranked among companies with meaningful P/E(ttm) only.
ZTS' s 10-Year P/E(ttm) Range
Min: 27.31  Med: 35.97 Max: 42.59
Current: 41.35
27.31
42.59
Forward P/E 25.91
ZTS's Forward P/E is ranked lower than
55% of the 233 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 24.27 vs. ZTS: 25.91 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 41.90
ZTS's PE(NRI) is ranked lower than
58% of the 472 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 35.00 vs. ZTS: 41.90 )
Ranked among companies with meaningful PE(NRI) only.
ZTS' s 10-Year PE(NRI) Range
Min: 27.31  Med: 35.97 Max: 42.59
Current: 41.9
27.31
42.59
P/B 19.16
ZTS's P/B is ranked lower than
95% of the 671 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.55 vs. ZTS: 19.16 )
Ranked among companies with meaningful P/B only.
ZTS' s 10-Year P/B Range
Min: 12.65  Med: 17.39 Max: 24.37
Current: 19.16
12.65
24.37
P/S 5.13
ZTS's P/S is ranked lower than
64% of the 649 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.43 vs. ZTS: 5.13 )
Ranked among companies with meaningful P/S only.
ZTS' s 10-Year P/S Range
Min: 3.11  Med: 3.66 Max: 5.27
Current: 5.13
3.11
5.27
PFCF 46.53
ZTS's PFCF is ranked higher than
51% of the 275 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 49.38 vs. ZTS: 46.53 )
Ranked among companies with meaningful PFCF only.
ZTS' s 10-Year PFCF Range
Min: 25.57  Med: 45.01 Max: 90.29
Current: 46.53
25.57
90.29
POCF 34.64
ZTS's POCF is ranked lower than
56% of the 384 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 29.86 vs. ZTS: 34.64 )
Ranked among companies with meaningful POCF only.
ZTS' s 10-Year POCF Range
Min: 21.59  Med: 30.28 Max: 41.99
Current: 34.64
21.59
41.99
EV-to-EBIT 29.08
ZTS's EV-to-EBIT is ranked lower than
55% of the 486 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.52 vs. ZTS: 29.08 )
Ranked among companies with meaningful EV-to-EBIT only.
ZTS' s 10-Year EV-to-EBIT Range
Min: 20.9  Med: 26.20 Max: 30
Current: 29.08
20.9
30
Current Ratio 2.27
ZTS's Current Ratio is ranked lower than
51% of the 608 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.29 vs. ZTS: 2.27 )
Ranked among companies with meaningful Current Ratio only.
ZTS' s 10-Year Current Ratio Range
Min: 2.27  Med: 2.80 Max: 3.47
Current: 2.27
2.27
3.47
Quick Ratio 1.29
ZTS's Quick Ratio is ranked lower than
64% of the 607 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.68 vs. ZTS: 1.29 )
Ranked among companies with meaningful Quick Ratio only.
ZTS' s 10-Year Quick Ratio Range
Min: 1.29  Med: 1.55 Max: 2
Current: 1.29
1.29
2
Days Inventory 281.34
ZTS's Days Inventory is ranked lower than
92% of the 621 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.49 vs. ZTS: 281.34 )
Ranked among companies with meaningful Days Inventory only.
ZTS' s 10-Year Days Inventory Range
Min: 117.43  Med: 277.80 Max: 288.46
Current: 281.34
117.43
288.46
Days Sales Outstanding 68.96
ZTS's Days Sales Outstanding is ranked higher than
52% of the 592 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 72.86 vs. ZTS: 68.96 )
Ranked among companies with meaningful Days Sales Outstanding only.
ZTS' s 10-Year Days Sales Outstanding Range
Min: 74.75  Med: 75.43 Max: 91.07
Current: 68.96
74.75
91.07

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.64
ZTS's Dividend Yield is ranked lower than
74% of the 637 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.29 vs. ZTS: 0.64 )
Ranked among companies with meaningful Dividend Yield only.
ZTS' s 10-Year Dividend Yield Range
Min: 0.21  Med: 0.73 Max: 0.94
Current: 0.64
0.21
0.94
Dividend Payout 0.32
ZTS's Dividend Payout is ranked lower than
51% of the 393 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.32 vs. ZTS: 0.32 )
Ranked among companies with meaningful Dividend Payout only.
ZTS' s 10-Year Dividend Payout Range
Min: 0.22  Med: 0.26 Max: 0.5
Current: 0.32
0.22
0.5
Yield on cost (5-Year) 0.63
ZTS's Yield on cost (5-Year) is ranked lower than
75% of the 641 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.34 vs. ZTS: 0.63 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
ZTS' s 10-Year Yield on cost (5-Year) Range
Min: 0.21  Med: 0.73 Max: 0.94
Current: 0.63
0.21
0.94
Share Buyback Rate -0.10
ZTS's Share Buyback Rate is ranked higher than
74% of the 463 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -3.00 vs. ZTS: -0.10 )
Ranked among companies with meaningful Share Buyback Rate only.
ZTS' s 10-Year Share Buyback Rate Range
Min: 0  Med: 0.00 Max: -0.1
Current: -0.1

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 1.42
ZTS's Price/Median PS Value is ranked lower than
52% of the 606 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.40 vs. ZTS: 1.42 )
Ranked among companies with meaningful Price/Median PS Value only.
ZTS' s 10-Year Price/Median PS Value Range
Min: 0.87  Med: 0.98 Max: 1.33
Current: 1.42
0.87
1.33
Earnings Yield (Greenblatt) (%) 3.44
ZTS's Earnings Yield (Greenblatt) (%) is ranked higher than
61% of the 687 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.30 vs. ZTS: 3.44 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ZTS' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 3.3  Med: 3.80 Max: 4.8
Current: 3.44
3.3
4.8

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare: » details
Traded in other countries:ZOE.Germany,
Zoetis Inc was incorporated in Delaware in July 2012. It is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. It markets products across four regions: the United States, Europe/Africa/Middle East, Canada/Latin America and Asia/Pacific; eight core species: the livestock species of cattle, swine, poultry, sheep and fish, and the companion animal species of dogs, cats and horses; and five product categories: anti-infectives - products that prevent, kill or slow the growth of bacteria, fungi or protozoa; vaccines - biological preparations that help prevent diseases of the respiratory, gastrointestinal and reproductive tracts or induce a specific immune response; parasiticides - products that prevent or eliminate external and internal parasites such as fleas, ticks and worms; medicated feed additives; and other pharmaceutical products - pain and sedation, oncology, antiemetic, allergy and dermatology; and reproductive products. The Company organizes and operates its business in four segments: the United States, Europe/Africa/Middle East, Canada/Latin America and Asia/Pacific. The Company sells its livestock products directly to a diverse set of livestock producers, including beef and dairy farmers as well as pork, poultry and aquaculture operations, and to veterinarians, third-party veterinary distributors and retail outlets that typically then sell the products to livestock producers. It primarily sells its companion animal products to veterinarians or to third-party veterinary distributors that typically then sell its products to veterinarians, and in each case veterinarians then typically sell its products to pet owners. Its primary competitors include animal health medicines and vaccines companies such as Merck Animal Health, the animal health division of Merck & Co., Inc. (formerly known as Intervet/Schering-Plough); Merial, the animal health division of Sanofi S.A.; Elanco, the animal health division of Eli Lilly and Company; Bayer Animal Health, the animal health division of Bayer AG; Novartis Animal Health, the animal health division of Novartis AG; and Boehringer Ingelheim Animal Health, the animal health division of Boehringer Ingelheim GmbH. In addition, it competes with hundreds of other animal health product producers throughout the world.
» More Articles for ZTS

Headlines

Articles On GuruFocus.com
Acquisition in the Health Care Industry Increased Volatility Jun 27 2015 
Bill Ackman is keeping on buying Zoetis Feb 24 2015 
Activist Investor Bill Ackman's Newest Additions to His Portfolio Feb 18 2015 
Feeling Good With This Med Company Jan 20 2015 
2015 - First Half Jan 01 2015 
Zoetis in a Growing Global Animal Health Industry Dec 03 2014 
Ackman’s Pershing Group Buys Stake in Zoetis Nov 13 2014 
Activist Bill Ackman Buys Big Stake In Animal Healthcare Company Zoetis Nov 12 2014 
Zoetis Will Benefit from Industry Trends Oct 07 2014 
Guru Stocks at 52-Week Lows: HMC, NMR, SDRL, ZTS, BBBY Apr 21 2014 

More From Other Websites
Valeant Clears Buy Point, Paces Top Medical Stocks Jul 23 2015
Dealpolitik: Activism Makes Corporate Governance More Complex at Zoetis Jul 23 2015
Merrill Lynch Makes Huge Social Media Addition to US 1 List Jul 22 2015
Zoetis Declares Third Quarter 2015 Dividend Jul 21 2015
ZOETIS INC. Files SEC form 8-K, Regulation FD Disclosure Jul 21 2015
Zoetis Declares Third Quarter 2015 Dividend Jul 21 2015
Video: Volatility signal in futures Jul 17 2015
Zoetis seen holding after earnings Jul 17 2015
Caution! 5 Heavily-Followed Dividend-Paying Stocks to Avoid Jul 14 2015
ZOETIS INC. Files SEC form 8-K, Results of Operations and Financial Condition Jul 10 2015
5 Stocks With Big Insider Buying Jul 08 2015
Billionaires George Soros and James Dinan Love These Stocks Jul 02 2015
Zoetis to Host Webcast and Conference Call on Second Quarter 2015 Financial Results Jul 02 2015
Zoetis to Host Webcast and Conference Call on Second Quarter 2015 Financial Results Jun 30 2015
3 Health Care M&A Deals and How Billionaire Investors are Playing Them Jun 29 2015
Canaccord Believes Zoetis Could Bid For Idexx Laboratories Jun 29 2015
Zoetis Inc (ZTS) Tumbles After Acquisition Rumors Prove To Be Unfounded Jun 28 2015
Valeant Shouldn’t Overfarm Deal Field Jun 26 2015
Nike lifts Dow but Nasdaq drops Jun 26 2015
Zoetis Loses All Of Thursday's Spike On Valeant Buzz Jun 26 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK